

05 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/05/3161328/0/en/Abivax-Announces-Late-Breaking-Presentation-of-8-Week-ABTECT-Trial-Results-with-Updated-Safety-Data.html

29 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/29/3158107/0/en/Abivax-Announces-Acceptance-of-Additional-Late-Breaking-Abstract-from-the-ABTECT-Phase-3-Induction-Trials-to-be-Presented-at-2025-United-European-Gastroenterology-UEG-Meeting.html

23 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/23/3155082/0/en/Abivax-Announces-Presentation-of-Late-Breaking-Abstract-for-Obefazimod-from-the-ABTECT-Phase-3-Induction-Trials-at-2025-United-European-Gastroenterology-UEG-Meeting.html

22 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/22/3119843/0/en/Abivax-Announces-Positive-Phase-3-Results-from-Both-ABTECT-8-Week-Induction-Trials-Investigating-Obefazimod-its-First-in-Class-Oral-miR-124-Enhancer-in-Moderate-to-Severely-Active-.html

23 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/23/3014599/0/en/Abivax-Announces-Presentation-of-Seven-Abstracts-for-Obefazimod-in-Ulcerative-Colitis-at-2025-European-Crohn-s-and-Colitis-Organization-20th-Annual-Congress.html

03 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/03/2958005/0/en/Abivax-Announces-First-Patient-Enrolled-in-ENHANCE-CD-the-Phase-2b-Trial-of-Obefazimod-in-Crohn-s-Disease.html